Tuberculosis treatment for the beginning of the next century

International Journal of Tuberculosis and Lung Disease

Volumn 3, Issue 8, 1999, Pages 651-662

  Schraufnagel, Dean E ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Treatment; Tuberculosis

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CELL ADHESION MOLECULE; CLOFAZIMINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; MACROLIDE; NITROIMIDAZOLE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMYCIN; TUBERCULOSTATIC AGENT; VITAMIN D;

BCG VACCINATION; DRUG DELIVERY SYSTEM; GENE THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; IMMUNOTHERAPY; INFECTION; MYCOBACTERIUM TUBERCULOSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG DESIGN; GENE THERAPY; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 0032797522     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (176)

1. Villemin J A. Cause et nature de la tuberculose : son inoculation de l'homme au lapin. Compt Rend Acad Sci 1865; 61: 1012-1015.
2. Koch R. Die Aetiologie der Tuberculose. Berlin Klin Wochen 1882; 19: 221-230.
3. Maggi N, Pasqualucci C R, Ballota R, Sensi P. Rifampicin: a new orally active rifamycin. Chemotherapy 1966; 11: 285-292.
4. Sudre P, Ten Dam G, Kochi A. Tuberculosis: a global overview of the situation today. Bull World Health Organ 1992; 70: 149-159.
5. Bates J H. Tuberculosis chemotherapy. The need for new antituberculosis drugs is urgent. Am J Respir Crit Care Med 1995; 151: 942-943.
6. Schatz A, Waksman S A. Effect of streptomycin and other antibiotic substances on Mycobacterium tuberculosis and related organisms. Proc Soc Exp Biol Med 1944; 57: 244-248.
7. Waksman S A. The conquest of tuberculosis. Berkeley, CA: University of California Press: 1964.
8. Chinnaswamy J, Reddy M V, Kailasam S, O'Sullivan J F, Gangadharam P R J. Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis. In vitro, intracellular, and in vivo studies. Am J Respir Crit Care Med 1995; 151: 1083-1086.
9. Reddy M V, Geeta N, Daneluzzi D, O'Sullivan J F, Gangadharam PRJ. Antituberculosis activities of clofazimine and its new analogs B4154 and B4157. Antimicrob Agents Chemother 1996; 40: 633-636.
10. Shafran S D, Singer J, Zarowny D P, et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. N Engl J Med 1996; 335: 377-383.
11. Chaisson R E, Keiser P, Pierce M, et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS 1997; 11: 311-317.
12. Nightingale S D, Cameron W, Gordin F M, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infections in AIDS. N Engl J Med 1993; 329: 828-833.
13. Sanfilippo A, Della Bruna C, Marsili L, et al. Biological activity of a new class of rifamycins, spiropiperdyl-rifamycins. J Antibiot 1980; 33: 1193-1198.
14. Hong Kong Chest Service/British Medical Research Council. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Tubercle Lung Dis 1992; 73: 59-67.
15. Chan S L, Yew W W, Ma W K, et al. The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis. Tubercle Lung Dis 1992; 73: 33-38.
16. McGregor M M, Olliaro P, Wolmarans L, et al. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed tuberculosis. Am J Respir Crit Care Med 1996; 154: 1462-1467.
17. Schwander S, Rusch-Gerdes S, Mateega A, et al. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. Tubercle Lung Dis 1995; 76: 210-218.
18. Tseng A L, Walmsley S L. Rifabutin-associated uveitis. Ann Pharmacother 1995; 29: 1149-1155.
19. Sullam P M, Gordin F M, Wynne B A. Efficacy of rifabutin in the treatment of disseminated infection due to Mycobacterium avium complex. The Rifabutin Treatment Group. Clin Infect Dis 1994; 19: 84-86.
20. Gordin F, Masur H. Prophylaxis of Mycobacterium avium complex bacteremia in patients with AIDS. Clin Infect Dis 1994; 18 (Suppl 3): S223-S226.
21. Centers for Disease Control. Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. MMWR Morb Mortal Wkly Rep 1996; 45: 921-925.
22. Gonzalez Montaner L J, Natal S, Yongchaiyud P, Olliaro P, the Rifabutin Study Group. Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin. Tubercle Lung Dis 1994; 75: 341-347.
23. Truffot-Pernot C, Lounis N, Grosset J H, Ji B. Clarithromycin is inactive against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995; 39: 2827-2828.
24. Luna Herrera J, Reddy MV, Daneluzzi D, Gangadharam P R J. Antituberculosis activity of clarithromycin. Antimicrob Agents Chemother 1995; 39: 2692-2695.
25. Kwon H H, Tomioka H, Saito H. Distribution and characterization of β-lactamases of mycobacteria and related organisms. Tubercle Lung Dis 1995; 76: 141-148.
26. Cynamon M H, Palmer G S. In vitro activity of amoxycillin in combination with clavulanic acid against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1983; 24: 429-431.
27. Casal M, Rodriguez F, Benavente M, Luna M. In vitro susceptibility of Mycobacterium tuberculosis, Mycobacterium bovis and Mycobacterium kansasii to amoxycillin and ticarcillin in combination with clavulanic acid. Eur J Clin Microbiol 1986; 5: 453-454.
28. Nadler J P, Berger J, Nord J A, Cofsky R, Saxena M. Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis. Chest 1991; 99: 1025-1026.
29. Yew W W, Wong W F, Lee J, Wong P C, Chau C H. Do β-lactams-β-lactamase inhibitor combinations have a place in the treatment of multidrug-resistant tuberculosis? Tubercle Lung Dis 1995; 76: 90-92.
30. Zhang Y, Steingrube V A, Wallace R J J. Beta-lactamase inhibitors and inducibility of beta-lactamase of Mycobacterium tuberculosis. Am Rev Respir Dis 1992; 145: 657-660.
31. Kanyok T P, Reddy M V, Chinnaswamy J, Danziger L H, Gangadharam P R J. In vitro activity of paromomycin against susceptible and multidrug-resistant Mycbacterium tuberculosis and M. avium complex strains. Antimicrob Agents Chemother 1994; 38: 170-173.
32. Kanyok T P, Reddy M V, Chinnaswamy J, Danziger L H, Gangadharam P R J. Activities of aminosidine (paromomycin) for Mycobacterium tuberculosis and Mycobacterium avium. J Antimicrob Chemother 1994; 33: 323-327.
33. Tsukamura M, Mizuno S, Murata H, Oshima T. Critical concentrations for resistances of tubercle bacilli to tuberactinomycin-N, viomycin, capreomycin, and lividomycin in patients with these agents. Kekkaku 1975; 50: 123-130.
34. Tsukamura M. A comparison of the time of in vivo resistance development of tubercle bacilli to rifampicin, kanamycin, ethionamide, lividomycin, and enviomycin (tuberactinomycin-N) in patients with chronic cavitary tuberculosis. Kekkaku 1978; 53: 495-498.
35. Suo J, Lin T P, Chiang C Y, Lee C N, Yu M C. Treatment of multidrug-resistant tuberculosis in Taiwan. Chemotherapy 1996; 42 (Suppl 3): 20-23.
36. Kennedy N, Fox R, Kisyombe G M, et al. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. Am Rev Respir Dis 1993; 148: 1547-1551.
37. Libenson V S, Braude V I. Eksperimental'noe issledovanie protivotuberkuleznoi aktivnosti aminazina. Biull Eksp Biol Med 1967; 63: 61-63.
38. Crowle A J, Douvas G S, May M H. Chlorpromazine: a drug potentially useful for treating mycobacterial infections. Chemotherapy 1992; 38: 410-419.
39. Ratnakar P, Murthy P S. Antitubercular activity of trifluoperazine, a calmodulin antagonist. FEMS Microbiol Eett 1992; 76: 73-76.
40. Dowling G S, Prosser-Thomas E W. Treatment of lupus vulgaris with calciferol. Lancet 1946; 1: 919-922.
41. 3 by cells recovered from bronchoalveolar lavage and the role of this metabolite in calcium homeostasis. Am Rev Respir Dis 1988; 138: 984-989.
42. Rook G A W, Steele J, Fraher L, et al. Vitamin D3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. Immunology 1986; 57: 159-163.
43. 3 metabolites and tumour necrosis factor in the pathogenesis of tuberculosis. Immunology 1987; 62: 229-234.
44. Denis M. Killing of Mycobacterium tuberculosis within human monocytes: activation by cytokines and calcitrol. Clin Exp Immonol 1991; 84: 200-206.
45. Brincourt J. Le calciferol a-t-il une action liquefiante sur le caseum? Poumon Coeur 1967; 23: 841-851.
46. Thomas M K, Lloyd-Jones D M, Thadhani R I, et al. Hypovitaminosis D in medical inpatients. N Engl J Med 1998; 338: 777-783.
47. Chan T Y. Differences in vitamin D status and calcium intake: possible explanations for the regional variations in the prevalence of hypercalcemia in tuberculosis. Calcif Tissue Int 1997; 60: 91-93.
48. Rook G A W. The role of vitamin D in the treatment of tuberculosis. Am Rev Respir Dis 1988; 138: 768-770.
49. Davies P D O. Vitamin D theory gets another airing. Int J Tuberc Eung Dis 1997; 1: 584.
50. Crowle A J, Salfinger M, May M H. 1,25(OH)2-vitamin D3 synergizes with pyrazinamide to kill tubercle bacilli in cultured human macrophages. Am Rev Respir Dis 1989; 139: 549-552.
51. Lochner J D, Schneider D J. Die verwantskap tussen tuberkulose, vitamien D, kalsium en VIGS. 'n Boodskap vir Suid-Afrika? S Afr Med J 1994; 84: 79-82.
52. Crowle A J, Ross E J. Inhibition by retinoic acid of multiplication of virulent tubercle bacilli in cultured human macrophages. Infect Immun 1989; 57: 840-844.
53. Mor N, Esfandiari A. Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages. Antimicrob Agents Chemother 1997; 41: 2035-2036.
54. Victor T C, Warren R, Butt J L, et al. Genome and MIC stability in Mycobacterium tuberculosis and indications for continuation of use of isoniazid in multidrug-resistant tuberculosis. J Med Microbiol 1997; 46: 847-857.
55. Stewart S M, Crofton J W. The clinical significance of low degrees of drug resistance in pulmonary tuberculosis. Am Rev Respir Dis 1964; 89: 811-829.
56. Bignall J R, Lind A, Rist N. A comparison of regimens of ethionamide, pyrazinamide and cycloserine in re-treatment of patients with pulmonary tuberculosis. Bull Int Union Tuberc 1969; 42: 7-57.
57. Heyrn B, Alzari P M, Honore N, Cole S T. Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol Microbiol 1995; 15: 235-245.
58. Halsey N A, Coberly J S, Desormeaux J, et al. Randomised trial of isoniazid versus rifampin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998; 351: 786-792.
59. Bass J B Jr., Farer L S, Hopewell P C, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. Am J Respir Crit Care Med 1994; 149: 1359-1374.
60. Centers for Disease Control. Essential components of a tuberculosis prevention and control program. Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Morb Mortal Wkly Rep 1995; 44: 1-16.
61. World Health Organization/International Union Against Tuberculosis and Lung Disease. Anti-tuberculosis drug resistance in the world. Geneva: WHO, 1997.
62. Medda S, Das N, Mahato S B, Mahadevan P R, Basu M K. Glycoside-bearing liposomal delivery systems against macrophage-associated disorders involving Mycobacterium leprae and Mycobacterium tuberculosis. Indian J Biochem Biophys 1995; 32: 147-151.
63. Bermudez L E. Use of liposome preparation to treat mycobacterial infections. Immunobiology 1994; 191: 578-583.
64. Onyeji C O, Nightingale C H, Nicolau D P, Quintiliani R. Efficacies of liposome-encapsulated clarithromycin and ofloxacin against Mycobacterium avium M. intracellulare. Antimicrob Agents Chemother 1994; 38: 1433-1438.
65. Deol P, Khuller G K, Joshi K. Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Antimicrob Agents Chemother 1997; 41: 1211-1214.
66. Gangadharam P R J, Kailasam S, Srinivasan S, Wise D L. Experimental chemotherapy of tuberculosis using single dose treatment with isoniazid in biodegradable polymers. J Antimicrob Chemother 1994; 33 265-271.
67. Condos R, Rom W N, Schluger N W. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet 1997; 349: 1513-1515.
68. Biya Y, Lizhen Z, Fengying A, National Cooperative Group on the Clinical Study of Rifapentine. A clinical comparative study of Chinese-made rifapentine on chemotherapy of tuberculosis (followup results after 3 years). Chinese J Antibiotics 1992; 7: 313-322.
69. Tam C M, Chan S L, Lam C W, Dickinson J M, Mitchison D A. Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong. Int J Tuberc Lung Dis 1997; 1: 411-416.
70. Chapuis L, Ji B, Truffot-Pernot C, O'Brien R J, Raviglione M C, Grosset J H. Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. AmJ Respir Crit Care Med 1994; 150: 1355-1362.
71. Luna Herrera J. In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli. Antimicrob Agents Chemother 1995; 39: 440-444.
72. Hirata T, Saito H, Tomioks H, et al. In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995; 39: 2295-2303.
73. Moghazeh S L, Pan X, Ara n T, Stover C K, Musser J M, Kreiswirth B N. Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations Antimicrob Agents Chemother 1996; 40: 2655-2657.
74. Klemens S P, Cynamon M H Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 1996; 40: 298-301.
75. Reddy M V, Luna-Herrera J, Daneluzzi D, Gangadharam P R J. Chemotherapeutic activity of henzoxazinorifamycin, KRM-1648, against Mycobacterium tuberculosis in C57BL/6 mice. Tubercle Lung Dis 1996; 77: 154-159.
76. Bermudez L E, Kolonoski P, Young L S, Inderlied C B. Activity of KRM 1648 alone or in combination with ethambutol or clarithromycin against Mycobacterium avium in beige mouse model of disseminated infection. Antimicrob Agents Chemother 1994; 38: 1844-1848.
77. Della Bruna C, Ungheri D, Sebben G, Sanfilippo A. Laboratory evaluation of a new long-acting 3-azinomethylrifamycin FCE 22250. J Antibiot (Tokyo) 1985; 38: 779-786.
78. Dickinson J M, Mitchison D A. In vitro activities against mycobacteria of two long-acting rifamycins, FCE22807 and CGP40/469A (SPA-S-565). Tubercle 1990; 71: 109-115.
79. Berlin O G, Young L S, Bruckner D A. In vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis. J Antimicrob Chemother 1987; 19: 611-615.
80. Ji B, Lounis N, Truffot-Pernot C, Grosset J. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995; 39: 1341-1344.
81. Ji B, Truffot-Pernot C, Grosset J. In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis. Tubercle 1991; 72: 181-186.
82. Rastogi N, Goh K S. In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother 1991; 35: 1933-1936.
83. Lounis N, Grosset J, Truffot-Pernot C, Ji B. Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 1997; 41: 607-610.
84. Mizutani S. Chemotherapy of pulmonary Mycobacterium kansasii infection. Kekkaku 1996; 71: 527-531.
85. Franzblau S G, Chan G P, Garcia-Ignacio B G, et al. Clinical trial of fusidic acid for lepromatous leprosy. Antimicrob Agents Chemother 1994; 38: 1651-1654.
86. Witzig R S, Franzblau S G. Susceptibility of Mycobacterium kansasii to ofloxacin, sparfloxacin, clarithromycin, azithromycin, and fusidic acid. Antimicrob Agents Chemother 1993; 37: 1997-1999.
87. Famularo G, De Simone C, Tzantzoglou S, Trinchieri V, Moretti S, Tonietti G. In vivo and in vitro efficacy of fusidic acid in HIV infection. Ann N Y Acad Sci 1993; 685: 341-343.
88. Bermudez L E, Kolonoski P, Young L S. Roxithromycin alone and in combination with either ethambutol or levofloxacin for disseminated Mycobacterium avium infections in beige mice. Antimicrob Agents Chemother 1996; 40: 1033-1035.
89. Wayne L G, Sramek H A. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1994; 38: 2054-2058.
90. Desai C R, Heera S, Patel A, Babrekar A B, Mahashur A A, Kamut S R. Role of metronidazole in improving response and specific drug sensitivity in advanced pulmonary tuberculosis. J Assoc Physicians India 1989; 37: 694-697.
91. McGuire M S, Morales M, Franzblau S G. Ethnomedicine leads in new drug discovery for tuberculosis (Abstract). 36th ICAAC conference 1996: F217.
92. Cantrell C L, Lu T, Fronczek F R, Fischer N H, Adams L B, Franzblau S G. Antimycobacterial cycloartanes from Borrichia frutescens. J Nat Prod 1996; 59: 1131-1136.
93. Lu T, Vargas D, Franzblau S G, Fischer N H. Diterpenes from Solidago rugosa. Phytochemistry 1995; 38: 451-456.
94. Franzblau S G, Cross C. Comparative in vitro antimicrobial activity of Chinese medicinal herbs. J Ethnopharmacol 1986; 15: 279-288.
95. Goldstein B P, Candiani G, Arain T M, et al. Antimicrobial activity of MDL 63246, a new semisynthetic glycopeptide antibiotic. Antimicrob Agents Chemother 1995; .19: 1580-1588.
96. Shawar R M, Humble D J, Van Dalfsenm J M, et al. Rapid screening of natural products for antimycobacterial activity by using luciferase-expressing strains of Mycobacterium bovis BCG and Mycobacterium intracellulare. Antimicrob Agents Chemother 1997; 41: 570-574.
97. Donald P R, Lamprecht J H, Freestone M, et al. A randomized placebo-controlled trial of the efficacy of beta-sitosterol and its glucoside as adjuvants in the treatment of pulmonary tuberculosis. Int J Tuberc Lung Dis 1997; 1: 518-521.
98. Peters J, Kondo K L, Lee R K, Lin C K, Inderlied C B. In vitro activity of oxazolidinones against Mycobacterium avium complex. J Antimicrob Chemother 1995; 35: 675-679.
99. Barbachyn M R, Hutchinson D K, Brickner S J, et al. Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. J Med Chem 1996; 39: 680-685.
100. Watt B. In vitro sensitivities and treatment of less common mycobacteria. J Antimicrob Chemother 1997; 39: 567-574.
101. Ashtekar D R, Costa-Periera R, Shrinivasan T, Iyyer R, Vishvanathan N, Rittel W. Oxazolidnones, a new class of synthetic antituberculosis agent. In vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis. Diagn Microbiol Infect Dis 1991; 14: 465-471.
102. Chinnaswamy J, Allaudeen H S, Hunter R L. Activities of polaxamer CRL8131 against Mycobacterium tuberculosis in vitro and in vivo. Antimicrob Agents Chemother 1995; 39: 1349.
103. Gangadharam P R J, Pratt P F, Damle P B, Porter T R, Folkers K. Inhibition of Mycobacterium intracellulare by some vitamin K and ubiquinone analogues. Am Rev Respir Dis 1978; 118:467-473.
104. Adams D H, Lloyd A R. Chemokines: leucocyte recruitment and activation cytokines. Lancet 1997; 349: 490-495.
105. de Jong R, Janson A A, Faber W R, Naafs B, Ottenhoff T H. IL-2 and IL-12 act in synergy to overcome antigen-specific T cell unresponsiveness in mycobacterial disease. J Immunol 1997; 159: 786-793.
106. Bloom B R, Flynn J, McDonough K, Kress Y, Chan J. Experimental approaches to mechanisms of protection and pathogenesis in M. tuberculosis infection. Immunobiology 1994; 191: 526-536.
107. Luscinskas F W, Kiely J M, Dinh H, et al. In vitro inhibitory effect of IL-8 and other chemoattractants on neutrophilendothelial adhesive interactions. J Immunol 1992; 149: 2163-2171.
108. Van Zee K J, Fischer E, Hawer A S, et al. Effects of intravenous IL-8 administration in nonhuman primates. J Immunol 1992; 148: 1746-1752.
109. Furie M B, Randolph G J. Chemokines and tissue injury. Am J Pathol 1995; 146: 1287-1301.
110. Hirsch C S, Ellner J J, Blinkhorn R, Toossi Z. In vitro restoration of T cell responses in tuberculosis and augmentation of monocyte effector function against Mycobacterium tuberculosis by natural inhibitors of transforming growth factor-β. Proc Natl Acad Sci USA 1997; 94: 3926-3931.
111. Lowrie D B, Silva C L, Tascon R E. Genetic vaccination against tuberculosis. Springer Semin Immunopathol 1997; 19: 161-173.
112. Huygen K, Content J, Denis O, et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 1996; 2: 893-898.
113. Wallis R S, Ellner J J. Cytokines and tuberculosis. J Leukoc Biol 1994; 55: 676-681.
114. Ladel C H, Blum C, Dreher A, Reifenberg K, Kopf M, Kaufmann S H. Lethal tuberculosis in interleukin-6-deficient mutant mice. Infect Immun 1997; 65: 4843-4849.
115. Flynn J L, Chan J, Triebold K J, Dalton D K, Stewart T A, Bloom B R. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993; 178: 2249-2254.
116. Newport M J, Huxley C M, Huston S, et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 1996; 335: 1941-1949.
117. Chan J, Xing Y, Magliozzo R S, Bloom B R. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J Exp Med 1992; 175: 1111-1122.
118. Cooper A M, Dalton D K, Stewart T A, Griffin J P, Russell D G, Orme I M. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 1993; 178: 2243-2247.
119. Dalton D K, Pitts-Meek S, Keshav S, Figari I S, Bradley A, Stewart T A. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 1993; 259: 1739-1742.
120. Holland S M, Eisenstein E M, Kuhns D B, et al. Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report. N Engl J Med 1994; 330: 1348-1355.
121. Castro A G, Silva R A, Appelberg R: Endogenously produced IL-12 is required for the induction of protective T cells during Mycobacterium avium infections in mice. J Immunol 1995; 155:2013-2019.
122. Cooper A M, Roberts A D, Rhoades E R, Callahan J E, Getzy D M, Orme I M. The role of interleukin-12 in acquired immunity to Mycobacterium tuberculosis infection. Immunology 1995; 84: 423-432.
123. Yoshida A, Koide Y. Arabinofuranosyl-terminated and mannosylated lipoarabinomannans from Mycobacterium tuberculosis induce different levels of interleukin-12 expression in murine macrophages. Infect Immun 1997; 65: 1953-1955.
124. Zhang M, Gately M K, Wang E, et al. Interleukin 12 at the site of disease in tuberculosis. J Clin Invest 1994; 93: 1733-1739.
125. Kobayashi K, Nakata N, Kai M, Kasama T, Hanyuda Y, Hatano Y. Decreased expression of cytokines that induce type 1 helper T cell/interferon-gamma responses in genetically susceptible mice infected with Mycobacterium avium. Clin Immunol Immunopathol 1997; 85: 112-116.
126. Saunders B M, Zhan Y, Cheers C. Endogenous interleukin-12 is involved in resistance of mice to Mycobacterium avium complex infection. Infect Immun 1995; 63: 4011-4015.
127. Kobayashi K, Kasama T, Yamazaki J, et al. Protection of mice from Mycobacterium avium infection by recombinant interleukin-12. Antimicrob Agents Chemother 1995; 39: 1369-1371.
128. Flynn J E, Goldstein M M, Triebold K J, Sypek J, Wolf S, Bloom B R. IE-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J Immunol 1995; 155: 2515-2524.
129. Cooper A M, Magram J, Ferrante J, Orme I M. Interleukin 12 (IE-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis. J Exp Med 1997; 186: 39-45.
130. Kobayashi K, Yamazaki J, Kasama T, et al. Interleukin (IL)-12 deficiency in susceptible mice infected with Mycobacterium avium and amelioration of established infection by IL-12 replacement therapy. J Infect Dis 1996; 174: 564-573.
131. Denis M. Interleukin-12 (IL-12) augments cytolytic activity of natural killer cells toward Mycobacterium tuberculosis-infected human monocytes. Cell Immunol 1994; 156: 529-536.
132. Jeevan A, Asherson G L. Recombinant interleukin-2 limits the replication of Mycobacterium lepraemurium and Mycobacterium bovis BCG in mice. Lymphokine Res 1988; 7: 129-140.
133. Bermudez L E, Stevens P, Kolonoski P, Wu M, Young L S. Treatment of experimental disseminated Mycobacterium avium complex infection in mice with recombinant IL-2 and tumor necrosis factor. J Immunol 1989; 143: 2996-3000.
134. Johnson B J, Ress S R, Willcox P, et al. Clinical and immune responses of tuberculosis patients treated with low-dose IL-2 and multidrug therapy. Cytokines Mol Ther 1995; 1: 185-196.
135. Appelberg R, Orme I M. Effector mechanisms involved in cytokine-mediated bacteriostasis of Mycobacterium avium infections in murine macrophages. Immunology 1993; 80: 352-359.
136. Bermudez L E. Potential role of cytokines in disseminated mycobacterial infections. Eur J Clin Microbiol Infect Dis 1994; 13 (Suppl 2): S29-S33.
137. Cornea P, Vladutiu A, Marcovici G. The immuno-suppressive effect of thalidomide in experimental tuberculosis in guineapigs. Tubercle 1967; 48: 51-53.
138. Tramontana J M, Utaipat U, Molloy A, et al. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995; 1: 384-397.
139. Horne N W. Prednisolone in treatment of pulmonary tuberculosis. A controlled trial. Final report to the Research Committee of the Tuberculosis Society of Scotland. Br Med J 1960; 2: 1751.
140. Morris D. Trial of corticotrophin and prednisone with chemotherapy in pulmonary tuberculosis: a two-year radiographic follow-up. Tubercle 1963; 44: 484-486.
141. Horne N W. A critical evaluation of corticosteroids in tuberculosis. Adv Tuberc Res 1960; 15: 1.
142. Shijubo N, Imai K, Nakanishi F, Yachi A, Abe S. Elevated concentrations of circulating ICAM-1 in far advance miliary tuberculosis. Am Rev Respir Dis 1993; 1298-1301.
143. Lopez Ramirez G M, Rom W N, Ciotoli C, et al. Mycobacterium tuberculosis alters expression of adhesion molecules on monocytic cells. Infect Immun 1994; 62: 2515-2520.
144. Saha B, Das G, Vohra H, Garguly N K, Mishra G C. Macrophage-T cell interaction in experimental mycobacterial infection. Selective regulation of co-stimulatory molecules on Mycobacterium-infected macrophages and its implication in the suppression of cell-mediated immune response. Eur J Immunol 1994; 24: 2618-2624.
145. Pourshafie M R, Sonnenfeld G. Treatment of an infected murine macrophage cell line (J774A.1) with interferon-gamma but not tumor necrosis factor-alpha or live Mycobacterium intracellulare alone modulates the expression of adhesion molecules. J Interferon Cytokine Res 1997; 17: 69-75.
146. Brennan P J, Besra G S. Structure, function and biogenesis of the mycobacterial cell wall. Biochem Soc Trans 1997; 25: 188-194.
147. Belisle J T, Vissa V D, Sievert T, Takayama K, Brennan P J, Besra G S. Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 1997; 276: 1420-1422.
148. Slayden R A, Lee R E, Armour J W, et al. Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis. Antimicrob Agents Chemother 1996; 40: 2813-2819.
149. Takayama K, Kilburn J O. Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis. Antimicrob Agents Chemother 1989; 33: 1493-1499.
150. Khoo K H, Douglas E, Azaci P, et al. Truncated structural variants of lipoarabinomannan in ethambutol drug-resistant strains of Mycobacterium smegmatis. Inhibition of arabinan biosynthesis by ethambutol. J Biol Chem 1996; 271: 28682-28690.
151. Belanger A E, Besra G S, Ford M E, et al. The embAB genes of Mycobacterium avium encoce an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc Natl Acad Sci USA 1996; 93: 11919-11924.
152. Mikusova K, Slayden R A, Besra G S, Brennan P J. Biogenesis of the mycobacterial cell wall and the site of action of ethambutol. Antimicrob Agents Chemother 1995; 39: 2484-2489.
153. Brennan P J, Nikaido H. The envelope of mycobacteria. Annu Rev Biochem 1995; 64: 29-63.
154. Gangadharam P R J. New drugs and strategies for chemotherapy of tuberculosis. Chapter 13. In: Gangadharam P R J, Jenkins P A, eds. Mycobacteria II, Chemotherapy. New York: Chapman and Hall; 1998; pp 335-378.
155. Cole S T, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-544.
156. Doran J L, Pang Y, Mdluli K E, et al. Mycobacterium tuberculosis efpA encodes an efflux protein of the QacA transporter family. Clin Diagn Lab Immunol 1997; 4: 23-32.
157. Sherman D R, Mdluli K, Hickey M J, et al. Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science 1996; 272: 1641-1643.
158. Zhang Y, Heym B, Allen B, Young D, Cole S. The catalaseperoxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992; 358: 591-593.
159. Banerjee A, Dubnau E, Quemaid A, et al. inhA.. a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994; 263: 227-230.
160. Wilson T M, Collins D M. ahpC, a gene involved in isoniazid resistance of the Mycobacterium tuberculosis complex. Mol Microbiol 1996; 19: 1025-1034.
161. Telenti A, Imboden P, Marchesi F, et al. Detection of rifampin-resistant mutations in Mycobacterium tuberculosis. Lancet 1993; 341: 647-650.
162. Sreevatsan S, Pan X, Zhang Y, Kreiswirth B N, Musser J M. Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1997; 41: 636-640.
163. Takiff H E, Salazar L, Guerrero C, et al. Cloning and nucleotide sequence of the Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mechanisms. Antimicrob Agents Chemother 1994; 38: 773-780.
164. Finken M, Kirschner P, Meier A, Wrede A, Bottger E C. Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: alterations of the ribosomal S12 gene and point mutation within a functional 16S ribosomal RNA pseudoknot. Mol Microbiol 1993; 9: 1239-1246.
165. Nair J, Rouse D A, Bai G H, Morris S L. The rpsL gene and streptomycin resistance in single and multiple drug resistant strains of Mycobacterium tuberculosis. Mol Microbiol 1993; 10: 521-527.
166. Sreevatsan S, Stockbauer K E, Pan X, et al. Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations. Antimicrob Agents Chemother 1997; 41: 1677-1681.
167. Heym B, Zhang Y, Poulet S, Young D, Cole S T. Characterization of the katG gene encoding a catalase-peroxidase required for the isoniazid susceptibility of Mycobacterium tuberculosis. J Bacteriol 1993; 175: 4255-4259.
168. Wheeler P R, Anderson P M. Determination of the primary target for isoniazid in mycobacterial mycolic acid biosynthesis with Mycobacterium aurum A+. Biochem J 1996; 318: 451-457.
169. Quemard A, Sacchettini J C, Dessen A, et al. Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. Biochemistry 1995; 34: 8235-8241.
170. Rozwarski D A, Grant G A, Barton D H R, Jacobs W R Jr., Sacchettini J C. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 1998; 279: 98-102.
171. Dessen A, Quemard A, Blanchard J S, Jacobs W R Jr., Sacchettini J C. Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis. Science 1995; 267: 1638-1641.
172. Rom W N, Yie T A, Tchou-Wong K M. Development of a suicide gene as a novel approach to killing Mycobacterium tuberculosis. Am J Respir Crit Care Med 1997; 156: 1993-1998.
173. Foley-Thomas E M, Whipple D L, Bermudez L E, Barletta R G. Phage infection, transfection and transformation of Mycobacterium avium complex and Mycobacterium paratuberculosis. Microbiology 1995; 141: 1173-1181.
174. Lewis L A, Victor T C, Helden E G H, et al. Identification of C to T mutation at position -236 bp in the human NRAMPI gene promoter. Immunogenetics 1996; 44: 309-311.
175. Bellamy R, Ruwende C, Corrah T, McAdam K P W J, Whittle H C, Hill A V S. Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans. N Engl J Med 1998; 338: 640-644.
176. Huang J H, Oefner P J, Adi V, et al. Analysis of the NRAMP1 and IFN-gamma R1 genes in women with Mycobacterium avium-intracellulare pulmonary disease. Am J Respir Crit Care Med 1998; 157: 377-381.